129 related articles for article (PubMed ID: 33093370)
1. The Role of Cannabinoid Receptor Type 2 in the Bone Loss Associated With Pediatric Celiac Disease.
Tortora C; Punzo F; Argenziano M; Di Paola A; Tolone C; Strisciuglio C; Rossi F
J Pediatr Gastroenterol Nutr; 2020 Nov; 71(5):633-640. PubMed ID: 33093370
[TBL] [Abstract][Full Text] [Related]
2. Effects of CB2 and TRPV1 Stimulation on Osteoclast Overactivity Induced by Iron in Pediatric Inflammatory Bowel Disease.
Tortora C; Di Paola A; Creoli M; Argenziano M; Martinelli M; Miele E; Rossi F; Strisciuglio C
Inflamm Bowel Dis; 2022 Aug; 28(8):1244-1253. PubMed ID: 35472140
[TBL] [Abstract][Full Text] [Related]
3. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor.
Idris AI; Sophocleous A; Landao-Bassonga E; van't Hof RJ; Ralston SH
Endocrinology; 2008 Nov; 149(11):5619-26. PubMed ID: 18635663
[TBL] [Abstract][Full Text] [Related]
4. PKCβII-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity.
Bellini G; Torella M; Manzo I; Tortora C; Luongo L; Punzo F; Colacurci N; Nobili B; Maione S; Rossi F
Pharmacol Res; 2017 Jan; 115():267-274. PubMed ID: 27919827
[TBL] [Abstract][Full Text] [Related]
5. The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention.
Rossi F; Bellini G; Tolone C; Luongo L; Mancusi S; Papparella A; Sturgeon C; Fasano A; Nobili B; Perrone L; Maione S; del Giudice EM
Pharmacol Res; 2012 Jul; 66(1):88-94. PubMed ID: 22465144
[TBL] [Abstract][Full Text] [Related]
6. The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma.
Bellini G; Di Pinto D; Tortora C; Manzo I; Punzo F; Casale F; Rossi F
Curr Cancer Drug Targets; 2017; 17(7):650-656. PubMed ID: 27993113
[TBL] [Abstract][Full Text] [Related]
7. Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease.
Taranta A; Fortunati D; Longo M; Rucci N; Iacomino E; Aliberti F; Facciuto E; Migliaccio S; Bardella MT; Dubini A; Borghi MO; Saraifoger S; Teti A; Bianchi ML
J Bone Miner Res; 2004 Jul; 19(7):1112-21. PubMed ID: 15176994
[TBL] [Abstract][Full Text] [Related]
8. Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors.
Rossi F; Tortora C; Di Martino M; Di Paola A; Di Pinto D; Marrapodi MM; Argenziano M; Pota E
PLoS One; 2022; 17(7):e0271730. PubMed ID: 35862357
[TBL] [Abstract][Full Text] [Related]
9. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption.
Rossi F; Siniscalco D; Luongo L; De Petrocellis L; Bellini G; Petrosino S; Torella M; Santoro C; Nobili B; Perrotta S; Di Marzo V; Maione S
Bone; 2009 Mar; 44(3):476-84. PubMed ID: 19059369
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid Receptor 2 as Antiobesity Target: Inflammation, Fat Storage, and Browning Modulation.
Rossi F; Bellini G; Luongo L; Manzo I; Tolone S; Tortora C; Bernardo ME; Grandone A; Conforti A; Docimo L; Nobili B; Perrone L; Locatelli F; Maione S; Del Giudice EM
J Clin Endocrinol Metab; 2016 Sep; 101(9):3469-78. PubMed ID: 27294325
[TBL] [Abstract][Full Text] [Related]
11. Peripheral cannabinoid receptor, CB2, regulates bone mass.
Ofek O; Karsak M; Leclerc N; Fogel M; Frenkel B; Wright K; Tam J; Attar-Namdar M; Kram V; Shohami E; Mechoulam R; Zimmer A; Bab I
Proc Natl Acad Sci U S A; 2006 Jan; 103(3):696-701. PubMed ID: 16407142
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid Receptor 2 Agonist Prevents Local and Systemic Inflammatory Bone Destruction in Rheumatoid Arthritis.
Zhu M; Yu B; Bai J; Wang X; Guo X; Liu Y; Lin J; Hu S; Zhang W; Tao Y; Hu C; Yang H; Xu Y; Geng D
J Bone Miner Res; 2019 Apr; 34(4):739-751. PubMed ID: 30508319
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor kappa B ligand mediated osteoclastogenesis.
Geng DC; Xu YZ; Yang HL; Zhu GM; Wang XB; Zhu XS
Chin Med J (Engl); 2011 Feb; 124(4):586-90. PubMed ID: 21362286
[TBL] [Abstract][Full Text] [Related]
14. Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Celiac Disease.
Tortora C; Di Paola A; Argenziano M; Creoli M; Marrapodi MM; Cenni S; Tolone C; Rossi F; Strisciuglio C
Biomedicines; 2022 Apr; 10(4):. PubMed ID: 35453624
[TBL] [Abstract][Full Text] [Related]
15. Role of the Endocannabinoid/Endovanilloid System in the Modulation of Osteoclast Activity in Paget's Disease of Bone.
Paoletta M; Moretti A; Liguori S; Di Paola A; Tortora C; Argenziano M; Rossi F; Iolascon G
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576321
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
[TBL] [Abstract][Full Text] [Related]
17. The genetic ablation or pharmacological inhibition of TRPV1 signalling is beneficial for the restoration of quiescent osteoclast activity in ovariectomized mice.
Rossi F; Bellini G; Torella M; Tortora C; Manzo I; Giordano C; Guida F; Luongo L; Papale F; Rosso F; Nobili B; Maione S
Br J Pharmacol; 2014 May; 171(10):2621-30. PubMed ID: 24308803
[TBL] [Abstract][Full Text] [Related]
18. Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis.
Sophocleous A; Marino S; Logan JG; Mollat P; Ralston SH; Idris AI
J Biol Chem; 2015 Sep; 290(36):22049-60. PubMed ID: 26195631
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of titanium particle-induced inflammatory osteolysis through inactivation of cannabinoid receptor 2 by AM630.
Geng DC; Xu YZ; Yang HL; Zhu XS; Zhu GM; Wang XB
J Biomed Mater Res A; 2010 Oct; 95(1):321-6. PubMed ID: 20623669
[TBL] [Abstract][Full Text] [Related]
20. Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis.
Koek WNH; van der Eerden BCJ; Alves RDAM; van Driel M; Schreuders-Koedam M; Zillikens MC; van Leeuwen JPTM
Bone; 2017 Feb; 95():108-114. PubMed ID: 27845263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
